Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the ViiV Healthcare Clinical Study Identification Number or study title by entering text and clicking search.

 

41 found

Click the study title to find more information about the study.

VIIV-CNA109586
Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects

Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus I, Phase: 4, Clinical Study ID: CNA109586, Sponsor: ViiV
VIIV-EPZ104057
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects

Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus I, Phase: 4, Clinical Study ID: EPZ104057, Sponsor: ViiV
VIIV-CAL30001
A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients

Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus I, Phase: 3, Clinical Study ID: CAL30001, Sponsor: ViiV
VIIV-CNA106030
A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity

Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV
VIIV-ABC107442
A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir

Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus I, Phase: 4, Clinical Study ID: ABC107442, Sponsor: ViiV
VIIV-EPZ113734
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects

Medicine: abacavir/lamivudine, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: EPZ113734, Sponsor: ViiV
VIIV-ESS30008
A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.

Medicine: abacavir/lamivudine, Condition: Infection, Human Immunodeficiency Virus I, Phase: 3, Clinical Study ID: ESS30008, Sponsor: ViiV
VIIV-ESS30009
A phase III, randomized, open-label, multicenter study of the safety and efficacy of efavirenz versus tenofovir when administered in combination with the abacavir/lamivudine fixed-dose combination tablet as a once-daily regimen in antiretroviral-naive HIV-1 infected subjects.

Medicine: abacavir/lamivudine, Condition: Infection, Human Immunodeficiency Virus I, Phase: 3, Clinical Study ID: ESS30009, Sponsor: ViiV
VIIV-AZL30006
A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.

Medicine: abacavir/lamivudine/zidovudine, Condition: Infection, Human Immunodeficiency Virus, Phase: 3, Clinical Study ID: AZL30006, Sponsor: ViiV
VIIV-ESS 30005
A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)

Medicine: abacavir/lamivudine/zidovudine, Condition: Infection, Human Immunodeficiency Virus I, Phase: 4, Clinical Study ID: ESS 30005, Sponsor: ViiV
First Previous 1 2 3 4 5 Next Last